Outcome Parameter
Ara RM, Reynolds AV, Conway P.
The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK.
Rheumatology (Oxford). 2007 Aug;46(8):1338-44
Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J.
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
Ann Rheum Dis. 2004; 63(11):1438-44
Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM
Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis
Arthritis Rheum. 2004; 51(1):1-8
Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
Ann Rheum Dis. 2004; 63(6):665-70
